Nivolumab has received regulatory approval to be given by weight-based or flat dosing every two weeks or by flat dosing every four weeks. However, flat dosing would lead to unnecessarily high doses for patients with lower body weight, increasing the drug usage and probability of toxicity. We review the rationale of using a four-weekly hybrid dosing strategy using weight-based and flat-dosing regimens adopted by some jurisdictions.
ZhaoXSuryawanshiSHruskaMet al.Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol2017; 28(8): 2002–2008.
6.
AgrawalSFengYRoyAet al.Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy. J Immunother Cancer2015; 3(Suppl 2): P141.
7.
ZhaoXIvaturiVGopalakrishnanMet al.Abstract CT101: a model-based exposure-response (ER) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types. Cancer Res2017; 77(13 suppl): CT101, DOI: 10.1158/1538-7445.AM2017-CT101. Available on: http://cancerres.aacrjournals.org/content/77/13_Supplement/CT101 (accessed: 26 June 2018).
8.
LongGVTykodiSSSchneiderJGet al.Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol2018; 29(11): 2208–2213.
9.
European Medicines Agency. Opdivo assessment report. London, United Kingdom, 24 September 2015.
10.
Bristol-Myers Squibb Canada. Rational [sic] of maximum volume with fixed-dose nivolumab administration. Saint-Laurent, Quebec, Canada, 10 December 2018.
